Below is a LinkedIn discussion which unfortunately came to end after I posted additional topics of interest for further debate. I hope to continue this discussion by FIRST giving additional readers the opportunity to review the all previous comments and SECONDLY posting an updated version of the additional topics I presented on LinkedIn (see Transparency of Drug Pricing Data: Part 2).
And this is where the story ends...for now.
If you are still interested, See Transparency of Drug Pricing Data: Part 2
No comments:
Post a Comment